NovaBridge Biosciences appointed Martin Dewhurst as an independent director effective September 8, 2026, also adding him to its Audit and Compensation committees. The appointment gives investors a new board member with healthcare strategy, governance and advisory experience, while the company said his independent perspective will support board oversight and long-term value creation.

Key Highlights

  • Martin Dewhurst spent his career at McKinsey & Company from 1992 to April 2023.
  • Martin Dewhurst was appointed as an independent director effective September 8, 2026.
  • Dewhurst joined NovaBridge’s Audit Committee and Compensation Committee.

NovaBridge Biosciences (NASDAQ: NBP) appointed Martin Dewhurst as an independent director effective September 8, 2026. He also joined the Board’s Audit Committee and Compensation Committee.

Dewhurst Adds Healthcare Governance Experience

Dewhurst worked at McKinsey & Company from 1992 to April 2023. His earlier roles included engagement manager at Arthur Andersen & Co. and Marketing manager at BP Solar. He serves on Cytovation’s Remuneration Committee and chairs Distalmotion’s Audit Committee.

Board Oversight And Independent Perspective

The appointment followed the departure of independent director Liu Xin. NovaBridge thanked Liu for her service and contributions to the company. Chairman Fu Wei said Dewhurst’s healthcare, strategy and governance experience would add value as NovaBridge grows and evolves.